The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Leukemia

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2008.235PMID 18769451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Granulocyte colony-stimulating factor mobilized CFU-F can be found in the peripheral blood but have limited expansion potential

  2008cited by this paper
• Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

  2007cited by this paper
• Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

  2007cited by this paper
• Myeloma bone disease and proteasome inhibition therapies.

  2007cited by this paper
• Bortezomib inhibits human osteoclastogenesis

  2007cited by this paper
• Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations.

  2007cited by this paper
• Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin

  2007cited by this paper
• Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

  2007cited by this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin‐1 to angiopoietin‐2 and angiogenin correlate with disease severity

  2007cited by this paper
• The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.

  2007cited by this paper
• Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

  2006cited by this paper
• First‐line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

  2006cited by this paper
• Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

  2006cited by this paper
• Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

  2006cited by this paper
• Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients

  2006cited by this paper
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  2006cited by this paper
• Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.

  2006cited by this paper
• Response to bortezomib and activation of osteoblasts in multiple myeloma.

  2006cited by this paper
• Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

  2006cited by this paper
• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  2006cited by this paper
• Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.

  2006cited by this paper
• Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia.

  2005cited by this paper
• Evaluation and monitoring of response to therapy in multiple myeloma.

  2005cited by this paper
• Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

  2005cited by this paper
• Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

  2005cited by this paper
• The role of markers of bone remodeling in multiple myeloma.

  2005cited by this paper
• The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

  2005cited by this paper
• Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

  2004cited by this paper
• Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.

  2004cited by this paper
• Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

  2004cited by this paper
• Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.

  2003cited by this paper
• Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre‐treatment levels of S‐ICTP and U‐Ntx are predictive for early progression of the bone disease during standard chemotherapy

  2003cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

  2003cited by this paper
• Acute hemorrhagic leukoencephalitis in patients with acute myeloid leukemia in hematologic complete remission.

  1999cited by this paper
• Myeloma of bone.

  1952cited by this paper

• The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma

  2024cites this paper
• The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.

  2023cites this paper
• What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma

  2022cites this paper
• Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

  2021cites this paper
• Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

  2021cites this paper
• Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.

  2020cites this paper
• Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma

  2019cites this paper
• Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

  2019cites this paper
• Practical Considerations for Bone Health in Multiple Myeloma

  2018cites this paper
• Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma

  2018cites this paper
• Optimizing therapy in bortezomib-exposed patients with multiple myeloma

  2018cites this paper
• Prise en charge des lésions osseuses du myélome multiple : quelles particularités ?

  2017cites this paper
• DKK1 and sclerostin are early markers of relapse in multiple myeloma.

  2017cites this paper
• P‐Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors

  2017cites this paper
• Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

  2017cites this paper
• Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells

  2016cites this paper
• Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

  2016cites this paper
• Treatment of relapsed and refractory multiple myeloma

  2016cites this paper
• Current treatment landscape for relapsed and/or refractory multiple myeloma

  2015cites this paper
• The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

  2015cites this paper
• Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer.

  2015cites this paper
• Management of bone disease in multiple myeloma

  2014cites this paper
• Novel agents and new therapeutic approaches for treatment of multiple myeloma.

  2014cites this paper
• A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

  2014cites this paper
• Chemotherapy-induced neuropathy: A comprehensive survey.

  2014cites this paper
• The effects of bortezomib on bone disease in patients with multiple myeloma

  2014cites this paper
• Relapsed and refractory multiple myeloma: new therapeutic strategies.

  2014cites this paper
• VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT

  2014cites this paper
• Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.

  2014cites this paper
• Role of bone-anabolic agents in the treatment of breast cancer bone metastases

  2014cites this paper
• Sotatercept in patients with osteolytic lesions of multiple myeloma

  2014cites this paper
• Множественная миелома (лечение рецидивов и рефрактерных форм): обзор литературы и собственные данные. Часть III

  2014cites this paper
• Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

  2014cites this paper
• Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study

  2014cites this paper
• Multiple Myeloma and Other Hematological Malignancies

  2014cites this paper
• A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events

  2014cites this paper
• Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015

  2013cites this paper
• The role of bone metabolism parameters in the assessment of myeloma bone disease

  2013cites this paper
• Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients

  2013cites this paper
• The Effect of Novel Anti-myeloma Agents on Bone Metabolism

  2013cites this paper
• Role of Osteoblast in Myeloma Pathology

  2013cites this paper
• Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

  2013cites this paper
• A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

  2013cites this paper
• Effects of proteasome inhibitors on bone cancer.

  2013cites this paper
• Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma

  2013cites this paper
• Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

  2013cites this paper
• Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.

  2013cites this paper
• DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

  2013cites this paper
• Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”

  2013cites this paper
• The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.

  2012cites this paper
• Lenalidomide for the treatment of relapsed and refractory multiple myeloma

  2012cites this paper
• Prevention and Treatment of Myeloma Bone Disease

  2012cites this paper
• Proteasome inhibitors and bone disease.

  2012cites this paper
• Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

  2012cites this paper
• Impact of bortezomib on bone health in myeloma: a review of current evidence.

  2012influential citation
• Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.

  2012cites this paper
• Clinical experience with thalidomide and lenalidomide in multiple myeloma.

  2012cites this paper
• Chemotherapy-Induced Neuropathic Pain

  2012cites this paper
• Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012

  2012cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Review of Clinical Studies

  2012cites this paper
• Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

  2012cites this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cites this paper
• Bone Anabolic Agents for the Treatment of Multiple Myeloma

  2011cites this paper
• Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

  2011cites this paper
• Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth.

  2011cites this paper
• The impact of bortezomib on the risk of thrombosis in multiple myeloma.

  2011cites this paper
• Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.

  2011cites this paper
• Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

  2011cites this paper
• Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

  2011cites this paper
• Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions.

  2011cites this paper
• Consensus on the utility of bone markers in the malignant bone disease setting.

  2011cites this paper
• Bortezomib in relapsed and relapsed/ refractory multiple myeloma

  2011cites this paper
• Therapy of relapsed and refractory multiple myeloma.

  2011cites this paper
• Bone effects of cancer therapies: pros and cons

  2011cites this paper
• Emerging therapies for the treatment of relapsed or refractory multiple myeloma

  2011cites this paper
• Gain, but what, how much and at what cost?

  2010cites this paper
• Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

  2010cites this paper
• Advances in treatment for relapses and refractory multiple myeloma

  2010cites this paper
• Multiple myeloma.

  2010cites this paper
• Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

  2010cites this paper
• The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.

  2010cites this paper
• Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.

  2010cites this paper
• Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.

  2010cites this paper
• Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

  2010cites this paper
• Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.

  2010cites this paper
• Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

  2010cites this paper
• Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches

  2010cites this paper
• Biochemical Markers of Bone Remodeling in Multiple Myeloma

  2010cites this paper
• Dysregulation of the Receptor Activator of NF-κB Ligand and Osteoprotegerin Production Influence the Apoptosis of Multiple Myeloma Patients’ Bone Marrow Stromal Cells Co-Cultured with Myeloma Cells

  2010cites this paper
• The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

  2010cites this paper
• Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.

  2010cites this paper
• Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.

  2010cites this paper
• Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.

  2010cites this paper
• Novel Agents for Relapsed and/or Refractory Multiple Myeloma

  2009cites this paper
• International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

  2009cites this paper
• Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis

  2009cites this paper
• Pathogenesis and management of myeloma bone disease

  2009cites this paper
• Neurological adverse effects caused by cytotoxic and targeted therapies

  2009cites this paper
• Proteasome inhibitors in the treatment of multiple myeloma

  2009cites this paper
• Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)

  2009cites this paper